Cannabis seed companies stock
Headlines on the fledgling marijuana industry.
Canopy Growth shares slide on wider-than-expected loss
Two cannabis CEOs praise letter supporting SAFE Banking from U.S. senators
Here’s why Curaleaf looks past headwinds and sticks to 2022 revenue view
Acreage sees cannabis business sprouting in the Northeast
Green Thumb Industries CEO eyes cash flow in vein of Warren Buffett
Stifel cuts cannabis industry view as analysts weigh Tilray
|ACB||Aurora Cannabis Inc.||$2.14||-1.33||-38.33%|
|CRON||Cronos Group Inc.||$3.87||-0.10||-2.52%|
|WEED||Canopy Growth Corp.||$6.15||-0.97||-13.62%|
|TLRY||Tilray Brands Inc. Cl 2||$4.5500||-0.1100||-2.36%|
I’m a 39-year-old single dad with $600,000 saved — I want to retire at 50 but don’t know how. What should I do?
‘We’re headed for a family feud’: My father offered his 3 kids equal monetary gifts. My siblings took cash. I took stock. It’s soared in value — now they’re crying foul
I’m 60, a school bus driver and bartender with $165,000 saved for retirement and a spender mentality – ‘is there any hope for me?’
How the need for EV battery metals is creating a new gold rush
My mother-in-law moved into our rental home years ago and made $60,000 in upgrades. We now want to sell. Should we repay her?
My bank accidentally deposited $10K in my account. I reported it, then moved it to my savings account. Have I done enough?
I want year-round outdoor living — dry summers and no snow — on $4,000 a month. Where should I retire?
Here’s how much money you would have lost if you bought a Bored Ape Yacht Club NFT a month ago
Here’s how the growth of electric vehicles could impact ESG investing
Why the Dow finally bounced — and what it will take to convince investors it’s for real
More from Cannabis Watch
Leafly CEO rings Nasdaq bell on cannabis holiday
Yoko Miyashita sees New York as potential boom state for adult-use cannabis as she celebrates the unofficial cannabis holiday of April 20.
Urban-gro eyes 80% revenue growth as indoor farm specialist
Acquisitions and hiring are ahead for Urban-gro in 2022 as a provider of equipment and services for controlled environment agriculture.
Garden State legal cannabis licenses are taking longer than expected
New Jersey delays move to allow medical dispensaries to also sell to anyone over age 21 as rollout of legal cannabis drags well past original Feb. 22 deadline.
Trulieve says revenue guidance that lags Wall Street estimate is realistic; ‘It’s very solid,’ says CEO
CEO Kim Rivers eyes uptick in stores it acquired from Harvest and other positives, but sees macroeconomic uncertainty as a reality for 2022.
Cannabis company that DEA is allowing to grow for research purposes to list shares on Nasdaq
Bright Green Corp. discloses a total float of 157.6 million shares and plans to trade on the Nasdaq under the symbol “BGXX” in a direct listing with EF Hutton.
Cannabis stocks rally on flurry of federal moves toward legalization
The U.S. House of Representatives is preparing to vote on the MORE Act and the Senate OK’d a cannabis research effort, sparking a cannabis stock rally.
Cresco Labs is buying Columbia Care in major cannabis merger that will create biggest U.S. player
Cresco Labs is paying $2 billion in stock to buy Columbia Care in a deal that will add Virginia and New Jersey to its U.S. footprint as they roll out adult use cannabis.
Tiny cannabis software startup Jointly is offering workers a novel perk — reimbursements for weed purchases
CEO says perk will boost wellness, win talent, and counteract the stigma of cannabis use.
TerrAscend eyes more M&A after closing big acquisition of Gage
TerrAscend executive chairman Jason Wild sees growth potential in New Jersey, Michigan and through the Eastern U.S.
Curaleaf narrows quarterly loss and tops $1 billion in annual revenue for the first time
CEO Joe Bayern sees better 2022 ahead as cannabis industry looks past the impact of omicron.
Supreme Court could decide whether workers’ compensation can cover medical marijuana
High court asks for solicitor general opinion in a sign it could wade into a dispute surrounding insurance reimbursement for medical cannabis in Minnesota.
Green Thumb CEO eyes ‘wonderfully boring’ execution of new market growth plan
Cannabis company beats EPS and revenue target, but shares fall amid a broad market selloff.
Curaleaf moves to quash rumors that executives’ ties to Russia may lead to sanctions
U.S. cannabis company Curaleaf has told investors that it is not subject to any sanctions against Russia although it has some ties to the country.
Cannabis wholesaler Nabis eyes hot New York market
Nabis co-CEO Vince Ning takes aim at the Empire State after building up Nabis as the largest wholesale cannabis supplier in California.
New York is one step away from allowing farmers to grow marijuana plants
Both houses in the state legislature approve a bill to grant temporary permission to farmers to grow cannabis as New York gears up its cannabis license push.
Cannabis banking firm Safe Harbor going public via SPAC deal
Northern Lights Acquisition Corp. to buy Safe Harbor from Partner Colorado Credit Union in a $327 million deal for the cannabis financial services company.
Cannabis beverage company Cann gets backing from Green Thumb Industries and celebrity investors
Los Angeles-based cannabis beverage company nets $27 million in funding from Green Thumb Industries and a list of celebrities including actress Rosario Dawson.
Corrected Cannabis startup Wellfounded is pursuing a seed round of capital
Founder and CEO Sara Rotman looks to build out a line of wellness products as a cannabis entrepreneur and farmer seeking ‘smart money’ to expand.
Cannabis sales set to rise ahead of Super Bowl Sunday
Based on last year’s data, cannabis sales will rise ahead of the Super Bowl but dip on the day of the big game, a market research company says.
Canopy Growth doubles down on premium cannabis as losses narrow and revenue tops estimates
Cannabis company ups THC content in its Canadian flower business and makes inroads in the U.S. market with drinks and CBD gummies.
Copyright © 2022 MarketWatch, Inc. All rights reserved.
Dow Jones Network
The 5 Best Marijuana Stocks to Buy in 2022
Global cannabis sales should double by 2026 to $62.1 billion, with the U.S. accounting for most of this growth.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
These pot stocks will have investors seeing green in the new year.
For many investors, the new year brings new opportunities to find attractive stocks in high-growth industries. Among all the industries to choose from, there may not be a better blend of growth and value at the moment than cannabis stocks, specifically those in the United States.
According to estimates from cannabis analytics company BDSA, worldwide weed sales are expected to double from $31 billion in 2021 to $62.1 billion by 2026. The bulk of this nominal growth will originate in the United States.
Although marijuana stocks were a buzzkill last year after federal cannabis-reform measures once again failed to gain traction in Congress, they’re now about as inexpensive as they’ve ever been. With that being said, these are the five best marijuana stocks to buy in 2022.
Image source: Getty Images.
The easiest way to see green in the cannabis space is to buy the most nominally profitable pot stock: Trulieve Cannabis (TCNNF -1.01% ) .
Trulieve, like many of the stocks on this list, is a vertically integrated multi-state operator (MSO) that controls most aspects of the seed-to-sale process. But its path to profitability was a lot different than that of most pot stocks.
Instead of setting up shop in as many legalized states as possible, Trulieve focused most of its attention on Florida’s medical marijuana market. As of Dec. 30, Trulieve had 160 operating dispensaries nationwide, 112 of which were in the Sunshine State. Saturating Florida has allowed Trulieve to gobble up half of the state’s dried cannabis flower and oils market, all while keeping its marketing budget relatively low. The result: three consecutive years of profitability in an industry where only a handful of companies are currently profitable.
The excitement for 2022 revolves around Trulieve’s acquisition of MSO Harvest Health & Recreation, which was completed during the fourth quarter. Harvest Health’s home market is Arizona, which voted to legalize recreational weed in November 2020, and began retailing adult-use cannabis in January 2021. Trulieve has 17 dispensaries in the state and a clear pathway to leading market share.
With sales growth expected to top 50% in 2022, Trulieve looks like a bargain at roughly 26 times estimated earnings per share.
A hydroponic cannabis farm. Image source: Getty Images.
Ancillary cannabis plays haven’t fared nearly as well as I or other pundits would have expected. But one that looks ripe for the picking in 2022 is GrowGeneration (GRWG 7.51% ) .
GrowGen, as the company is better known, operates retail hydroponic and organic gardening centers in 13 states. Though the hydroponic (i.e., growing plants in a nutrient-rich water solvent), soil, nutrient, and lighting solutions offered by the company are helpful for consumers and enterprises of all industries, it’s of particular use to increasing crop yields for cannabis growers. Thus GrowGen is often viewed as a marijuana stock.
The company’s key to success has long been its aggressive acquisition strategy. Don’t get me wrong: GrowGen’s same-store sales have consistently risen by a double-digit percentage. However, the company’s bread and butter is acquiring locations in new and existing markets to quickly grow its brand.
In addition to acquisitions, management is focused on building up the company’s online presence, as well as promoting a number of proprietary and private-label brands that should provide a margin lift. The third quarter saw private-label and proprietary merchandise account for nearly 9% of total sales, which compares to more like 2% in the year-ago quarter.
After getting pummeled last year, shares of GrowGeneration can be scooped up for well under two times estimated sales for 2022.
The Planet 13 Las Vegas SuperStore. Image source: Planet 13.
Planet 13 Holdings
The best marijuana stocks to buy in 2022 are those that provide a competitive advantage and differentiation. Small-cap MSO Planet 13 Holdings (PLNH.F -1.32% ) fits that description well.
What makes Planet 13 unique is that the company is focused just as much on providing a memorable experience for cannabis enthusiasts as it is on making sales. The key differentiator here is the sheer size and functionality of its dispensaries.
Planet 13 has two operating dispensaries at the moment. The Las Vegas SuperStore spans 112,000 square feet and features a cafe, consumer-facing processing center, and events center, to go along with the biggest selection of pot products you’ll find in any U.S. dispensary. There’s also the Orange County SuperStore in Santa Ana, California, which spans 55,000 square feet, including 16,500 square feet of selling space.
Having visited the Las Vegas SuperStore, I was impressed by the incorporation of technology (self-pay kiosks), a store layout that funnels customers to higher-margin derivative products, and the provision of individual budtenders to meet customer needs.
The next tourist-heavy locations for Planet 13 dispensaries will be Chicago; Orlando, Florida, and Miami.
With the company on the verge of recurring profitability and gobbling up a significant portion of Nevada’s weed sales with just a single location, it has the look of a no-brainer buy.
Image source: Getty Images.
Another small-cap pot stock with serious potential in 2022 is MSO Jushi Holdings (JUSHF -6.84% ) .
To keep with the theme here, Jushi has a unique two-pronged strategy for growth.
First, it’s targeting a number of limited-license markets, like Pennsylvania, Illinois, Massachusetts, and Virginia. A limited-license state limits how many dispensary licenses are issued in total and/or to a single business. For big companies with deep pockets, limited-license markets can be a nuisance. But for Jushi, which has just 28 operating dispensaries nationwide, these limitations provide some degree of protection, allowing it to build up its brands and garner a loyal following.
Jushi’s other key catalyst has been prudently deploying cash for acquisitions. For example, the company acquired two dispensaries in Southern California last year. Though California has plenty of pot stores, it’s the leading market for marijuana sales in the world.
As a Jushi shareholder, I’ll also add that execs and other insiders were responsible for contributing $45 million of the first $250 million in capital raised by the company. When the financial interest of insiders align with that of shareholders, good things happen more often than not.
Image source: Getty Images.
The fifth and final best marijuana stock to buy in 2022 is MSO Cresco Labs (CRLBF -2.35% ) .
Similar to Jushi Holdings, Cresco Labs has a penchant for focusing most of its attention on limited-license states, at least with regard to its retail operations. The company has 45 operating dispensaries, with a presence in limited-license markets like Illinois, Ohio, and Massachusetts. Mixing in competitive high-dollar markets, such as Florida, with limited-license markets gives Cresco a path to sustainable double-digit retail growth.
But what really allows Cresco Labs to stand out is the company’s industry-leading wholesale operations. Wall Street isn’t a big fan of wholesale cannabis because the margins aren’t anything to speak of next to retail cannabis. But Cresco Labs can make up what it loses in margin with insane volume. That’s because it holds one of only a small handful of cannabis distribution licenses in California. This license allows it to place its proprietary pot products into more than 575 dispensaries throughout the Golden State.
Cresco Labs has all the tools and momentum necessary to reach recurring profitability in 2022. With the company now valued at well under two times estimated sales (per Wall Street) this year, it looks like a budding bargain.